Lincoln Pharmaceuticals cash flow

Latest FY26

Cash from operations: ₹106cr+14.3% on FY25
Capital spending: ₹26.0cr+36.8% on FY25
Free cash flow: ₹80.3cr+8.6% on FY25
Cash from financing: ₹0.2cr−₹6.4 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	14.5	12.9	10.6	9.2
	—	1.0	1.9	1.5	2.0
	—	−7.6	−7.2	−7.0	−6.2
	—	−0.3	−0.1	0.0	0.0
	—	−0.3	−4.2	−21.1	−4.4
	—	−0.9	−0.3	0.6	−0.2
	—	−0.1	−2.0	−1.4	−0.7
	—	−1.4	−1.5	−7.1	2.7
	—	5.8	−4.8	−26.1	−20.2
	—	−0.2	0.1	0.1	−0.2
	—	−0.1	−0.2	0.1	−0.2
	—	2.9	−5.5	−4.8	4.7
	—	0.1	−0.4	0.4	0.1
	—	−0.1	12.5	21.6	−20.5
	—	1.2	1.0	0.5	0.2
	—	0.7	1.8	−1.1	0.2
	—	−2.3	2.4	0.6	0.9
	—	2.9	3.7	−0.3	1.0
Cash from operating activities
	128	116	109	122	100
	—	15.9	10.1	−32.9	−31.6
	—	131	119	89.4	68.9
	—	25.1	26.3	26.2	29.6
	—	106	93.0	63.2	39.3
Cash from investing activities
	—	25.4	19.0	39.5	14.3
	—	0.6	0.0	0.0	0.0
	—	1.5	0.0	0.1	0.7
	—	69.1	85.1	99.6	63.2
	—	36.2	56.5	74.8	73.8
	—	96.7	53.0	97.0	44.0
	—	56.1	14.3	55.0	24.4
	—	0.3	0.0	0.0	0.0
	—	0.9	3.7	9.0	0.9
	—	−1.6	3.7	39.9	−15.0
	—	−98.4	−78.9	−57.3	−36.6
Cash from financing activities
	—	0.0	68.4	20.0	19.4
	—	−4.4	69.4	20.9	19.5
	—	3.6	3.6	3.0	3.0
	—	−0.7	−1.8	−1.3	−1.4
	—	0.2	−6.4	−5.2	−4.5
	—	8.1	7.7	0.7	−1.9
	—	8.1	7.7	0.7	−1.9
	—	—	—	5.7	5.1
Reference items
	99.6	97.7	101	99.9	89.2
	13.8%	14.6%	16.3%	17.2%	17.5%
	80.3	80.3	74.0	23.7	25.0
	₹40.10	₹40.10	₹36.94	₹11.85	₹12.47
	13.92×	—	—	—	—
	—	1.21×	1.13×	0.68×	0.54×
	—	25.1	26.3	26.2	29.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LINCOLN₹558.10

Lincoln Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersSIGACHI THEMISMED BAJAJHCARE AMRUTANJANJAGSNPHARM WANBURY AHCLMcap ₹1,118 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	9.2	10.6	12.9	14.5	—
+ Finance Costs	2.0	1.5	1.9	1.0	—
+ Interest Income	-6.2	-7.0	-7.2	-7.6	—
+ Dividend Income	0.0	0.0	-0.1	-0.3	—
+ Fair Value (Gains) / Losses	-4.4	-21.1	-4.2	-0.3	—
+ Other Non-cash Items	-0.2	0.6	-0.3	-0.9	—
+ Other Reconciling Items	-0.7	-1.4	-2.0	-0.1	—
Changes in Working Capital
+ Inventories	2.7	-7.1	-1.5	-1.4	—
+ Trade Receivables — Current	-20.2	-26.1	-4.8	5.8	—
+ Other Financial Assets — Current	-0.2	0.1	0.1	-0.2	—
+ Other Financial Assets — Non-current	-0.2	0.1	-0.2	-0.1	—
+ Other Current Assets	4.7	-4.8	-5.5	2.9	—
+ Other Non-current Assets	0.1	0.4	-0.4	0.1	—
+ Trade Payables — Current	-20.5	21.6	12.5	-0.1	—
+ Other Financial Liabilities — Current	0.2	0.5	1.0	1.2	—
+ Other Financial Liabilities — Non-current	0.2	-1.1	1.8	0.7	—
+ Other Current Liabilities	0.9	0.6	2.4	-2.3	—
+ Provisions — Current	1.0	-0.3	3.7	2.9	—
Cash from Operating Activities
Profit Before Tax (per I/S)	100.5	122.2	109.2	115.6	128.0
+ Total Adjustments (incl. Working Capital)	-31.6	-32.9	10.1	15.9	—
Cash from Operations (pre-tax)	68.9	89.4	119.3	131.5	—
+ Income Taxes Paid	29.6	26.2	26.3	25.1	—
Cash from Operating Activities	39.3	63.2	93.0	106.4	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	14.3	39.5	19.0	25.4	—
+ Acq of Intangible Assets	0.0	0.0	0.0	0.6	—
+ Disp of Fixed Assets	0.7	0.1	0.0	1.5	—
+ Acq of Investment Property	63.2	99.6	85.1	69.1	—
+ Disp of Investment Property	73.8	74.8	56.5	36.2	—
+ Loans & Advances Made	44.0	97.0	53.0	96.7	—
+ Loans & Advances Repaid	24.4	55.0	14.3	56.1	—
+ Dividends Received — Investing	0.0	0.0	0.0	0.3	—
+ Interest Received — Investing	0.9	9.0	3.7	0.9	—
+ Other Inflows / (Outflows) — Investing	-15.0	39.9	3.7	-1.6	—
Cash from Investing Activities	-36.6	-57.3	-78.9	-98.4	—
Cash from Financing Activities
+ Proceeds from Borrowings	19.4	20.0	68.4	0.0	—
+ Repayment of Borrowings	19.5	20.9	69.4	-4.4	—
+ Dividends Paid	3.0	3.0	3.6	3.6	—
+ Other Inflows / (Outflows) — Financing	-1.4	-1.3	-1.8	-0.7	—
Cash from Financing Activities	-4.5	-5.2	-6.4	0.2	—
Net Changes in Cash (pre-FX)	-1.9	0.7	7.7	8.1	—
Net Changes in Cash	-1.9	0.7	7.7	8.1	—
Closing Cash	5.1	5.7	—	—	—
Reference Items
EBITDA	89.2	99.9	101.5	97.7	99.6
EBITDA Margin %	17.48	17.21	16.29	14.56	13.79
Free Cash Flow (CFO − Capex)	25.0	23.7	74.0	80.3	80.3
Free Cash Flow per Basic Share	12.47	11.85	36.94	40.10	40.10
Price to Free Cash Flow	—	—	—	—	13.92
Cash Flow to Net Income	0.54	0.68	1.13	1.21	—
Cash Paid for Taxes	29.6	26.2	26.3	25.1	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.